Our top pick for
Marker Therapeutics, Inc is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Marker Therapeutics employs 28 staff and has a trailing 12-month revenue of around USD$679,979.
|Latest market close||USD$1.55|
|52-week range||USD$1.32 - USD$3.43|
|50-day moving average||USD$1.5354|
|200-day moving average||USD$1.8351|
|Wall St. target price||USD$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.165|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-13.41%|
|1 month (2020-12-15)||-0.64%|
|3 months (2020-10-15)||-0.64%|
|6 months (2020-07-15)||-16.22%|
|1 year (2020-01-15)||-49.35%|
|2 years (2019-01-15)||-72.66%|
|3 years (2018-01-12)||3.61|
|5 years (2016-01-15)||202.44%|
|Gross profit TTM||USD$-12,551,610|
|Return on assets TTM||-32.18%|
|Return on equity TTM||-64.42%|
|Market capitalisation||USD$81.6 million|
TTM: trailing 12 months
There are currently 3.6 million Marker Therapeutics shares held short by investors – that's known as Marker Therapeutics's "short interest". This figure is 0.1% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting Marker Therapeutics shares can be evaluated.
Marker Therapeutics's "short interest ratio" (SIR) is the quantity of Marker Therapeutics shares currently shorted divided by the average quantity of Marker Therapeutics shares traded daily (recently around 150277.68115942). Marker Therapeutics's SIR currently stands at 24.15. In other words for every 100,000 Marker Therapeutics shares traded daily on the market, roughly 24150 shares are currently held short.
However Marker Therapeutics's short interest can also be evaluated against the total number of Marker Therapeutics shares, or, against the total number of tradable Marker Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marker Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Marker Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1266% of the tradable shares (for every 100,000 tradable Marker Therapeutics shares, roughly 127 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Marker Therapeutics.
Find out more about how you can short Marker Therapeutics stock.
We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.
Marker Therapeutics's shares were split on a 1:12 basis on 16 September 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.
Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $1.32 up to $3.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.1657. This would suggest that Marker Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.